Loading...
CDTX logo

Cidara Therapeutics Community

NasdaqCM:CDTX Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 41 Fair Values set on narratives written by author

Community Investing Ideas

CDTX logo
Cidara Therapeutics

Cidara Therapeutics: The underestimated potential of CD388

Summary CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.Read more

View narrative
9users have liked this narrative
0users have commented on this narrative
34users have followed this narrative
US$100
3.8% overvalued intrinsic discount
birdflustocks Fair Value
Revenue growth
83.73% p.a.
Profit Margin
19.58%
Future PE
26.11x
Share price in 2035
US$7.22k